sb 203580 has been researched along with fostriecin in 1 studies
| Studies (sb 203580) | Trials (sb 203580) | Recent Studies (post-2010) (sb 203580) | Studies (fostriecin) | Trials (fostriecin) | Recent Studies (post-2010) (fostriecin) |
|---|---|---|---|---|---|
| 3,489 | 4 | 1,137 | 106 | 2 | 23 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Grethe, S; Pörn-Ares, MI | 1 |
1 other study(ies) available for sb 203580 and fostriecin
| Article | Year |
|---|---|
p38 MAPK regulates phosphorylation of Bad via PP2A-dependent suppression of the MEK1/2-ERK1/2 survival pathway in TNF-alpha induced endothelial apoptosis.
Topics: Alkenes; Apoptosis; bcl-Associated Death Protein; Cell Line; Cell Survival; Cells, Cultured; Down-Regulation; Endothelial Cells; Humans; Imidazoles; MAP Kinase Kinase 1; MAP Kinase Kinase 2; Marine Toxins; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Oxazoles; p38 Mitogen-Activated Protein Kinases; Phosphoprotein Phosphatases; Phosphorylation; Polyenes; Protein Phosphatase 2; Pyridines; Pyrones; Signal Transduction; Tumor Necrosis Factor-alpha | 2006 |